IMC Chicago
NTLA icon

IMC Chicago’s Intellia Therapeutics NTLA Stock Holding History

IMC Chicago’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$755K Sell
44,600
-41,100
-48% -$575K ﹤0.01% 4184
2026
Q1 		$1.1M Buy
85,700
+31,500
+58% +$401K ﹤0.01% 3185
2025
Q4 		$487K Buy
+54,200
New +$746K ﹤0.01% 3502

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IMC Chicago's NTLA Position: Q2 2026 in Review

IMC Chicago sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 12,771 shares — an estimated $179K sold.

IMC Chicago first reported a position in NTLA in Q4 2025 and held it in 2 quarters. The position peaked at $278K in Q4 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • IMC Chicago reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 12,771 Intellia Therapeutics shares in Q2 2026, an estimated $179K.
  • IMC Chicago first reported a position in Intellia Therapeutics in Q4 2025 and held it in 2 quarters.
  • IMC Chicago's Intellia Therapeutics position peaked at $278K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.